ConductScience.org, home

Paper40144682

Future perspectives on immunotherapy for hepatocellular carcinoma.

Chan LL and 1 other. Ther Adv Med Oncol, 2025. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Future perspectives on immunotherapy for hepatocellular carcinoma. Papers, record 40144682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40144682

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Future perspectives on immunotherapy for hepatocellular carcinoma.
PubMed
Journal
Ther Adv Med Oncol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.29, provisional
iCite
Revised in PubMed
2026-09-24
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chan LLLandon Lhttps://orcid.org/0000-0002-1306-5896
2Chan SLStephen L

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References116

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
141647284Neoadjuvant immunotherapy for early-stage hepatocellular carcinoma: the arts and science.ESMO Gastrointest Oncol2023https://conductscience.org/library/papers/41647284PubMed
239325464Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma.JAMA Oncol2024https://conductscience.org/library/papers/39325464PubMed
322004366Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis.J Gastroenterol Hepatol2012https://conductscience.org/library/papers/22004366PubMed
434986285Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.N Engl J Med2022https://conductscience.org/library/papers/34986285PubMed
533791252Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma.J Hepatocell Carcinoma2021https://conductscience.org/library/papers/33791252PubMed
631550417Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?Am J Transplant2020https://conductscience.org/library/papers/31550417PubMed
718650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
838086815Therapeutic cancer vaccines: advancements, challenges, and prospects.Signal Transduct Target Ther2023https://conductscience.org/library/papers/38086815PubMed
932104669The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma.J Hepatocell Carcinoma2020https://conductscience.org/library/papers/32104669PubMed
1038382875Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.Ann Oncol2024https://conductscience.org/library/papers/38382875PubMed
1136894804Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.J Gastroenterol2023https://conductscience.org/library/papers/36894804PubMed
1232735779Engineering CAR-T Cells for Next-Generation Cancer Therapy.Cancer Cell2020https://conductscience.org/library/papers/32735779PubMed
1334914889Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.Lancet Oncol2022https://conductscience.org/library/papers/34914889PubMed
1432127929Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma.J Cancer2020https://conductscience.org/library/papers/32127929PubMed
1536856617Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.N Engl J Med2023https://conductscience.org/library/papers/36856617PubMed
1639147893Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions.Nat Rev Gastroenterol Hepatol2024https://conductscience.org/library/papers/39147893PubMed
1712547409Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.J Hepatol2003https://conductscience.org/library/papers/12547409PubMed
1829040999Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.Dig Dis2017https://conductscience.org/library/papers/29040999PubMed
1933419761Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells.Cancer Discov2021https://conductscience.org/library/papers/33419761PubMed
2036108891Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma.Int J Radiat Oncol Biol Phys2023https://conductscience.org/library/papers/36108891PubMed

See all 116 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42566079Current status and challenges of immune checkpoint inhibitors in liver cancer: from monotherapy to combination strategies.Med Oncol2026https://conductscience.org/library/papers/42566079PubMed
42346124Immunotherapy and Hepatocellular Carcinoma: From Tumor-Immune Cell Interactions to Rational Therapeutic Strategies.Cells2026https://conductscience.org/library/papers/42346124PubMed
42255232Anlotinib plus penpulimab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the perspective of the Chinese healthcare system.Front Oncol2026https://conductscience.org/library/papers/42255232PubMed
42096002Knowledge mapping of ⁹⁰Y transarterial radioembolization combined with immunotherapy in hepatocellular carcinoma: a bibliometric analysis.Discov Oncol2026https://conductscience.org/library/papers/42096002PubMed
41166641Clinical management of liver cancer patients with immune checkpoint inhibitors treatment.Hepat Oncol2025https://conductscience.org/library/papers/41166641PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40144682

GET https://conductscience.org/api/papers/v1/40144682/references?page=2